RESUMO
Cancer is a major worldwide public health problem. With the popularity of medical examinations, the improvement of surgical procedures and the application of antitumor drugs, the mortality rate of cancer has declined in recent years, but the quantity remains extremely high. At the same time, with the emergence of tumor drug resistance, it is particularly urgent to seek new and effective drugs for tumor treatment. Solanine, a type of steroidal alkaloid, is the main extract of Solanum nigrum L. Because of its wide biological activity, it has attracted increasing attention, specifically, towards the empirical study of its antitumor activity. This article summarizes the research progress of the antitumor effect and mechanism of solanine over the past 20 years, to provide a reference for workers in the field of cancer research. Studies from 2000 to 2020 were reviewed from PubMed, Springer Link and the Web of Science using the keywords Solanum nigrum L., solanine, α-solanine, ß-solanine, γ-solanine, tumor, cancer and their combinations. Exclude research articles of extraction mixture. Language is limited to English. Solanine shows antitumor ability against different tumors by targeting different proteins. Although there is a lack of clinical large-scale studies, a large number of basic pharmacological and toxicological studies have confirmed that solanine may be a new effective cancer drug or adjuvant therapy. Solanine preparations and solanine derivative preparations have broad economic and scientific research prospects.
RESUMO
Background. Functional dyspepsia (FD) is a functional upper gastrointestinal disorder with significant morbidity and medical costs. Previous studies investigated the association of G-protein ß3 (GNB3) genetic polymorphisms with FD but with inconsistent results. Therefore, we performed a meta-analysis to derive a precise estimation of the relationship between GNB3 polymorphisms and FD. Methods. We searched different databases including PubMed, EMBASE, CNKI, and the Ovid Library to gather eligible studies on GNB3 polymorphisms and FD. The association was assessed by the odds ratio (OR) with 95% confidence intervals (CI). Results. We identified 12 studies with 1109 cases and 2853 controls for the analysis. We found no associations of GNB3 C825T polymorphism with FD in the overall population (T versus C, OR = 1.06, 95% CI: 0.96-1.18, P = 0.26; TT versus CC + CT, OR = 1.16, 95% CI: 0.97-1.39, P = 0.11; TT + CT versus CC, OR = 1.01, 95% CI: 0.77-1.31, P = 0.96; TT versus CC, OR = 1.15, 95% CI: 0.93-1.44, P = 0.20). Subgroup analyses by genotyping method indicated that the magnitude of association was strengthened for additive model (OR = 1.15, 95% CI: 1.07-2.24, P = 0.02). Sensitivity analysis did not reveal significant associations under all models. Conclusions. This meta-analysis demonstrates that GNB3 C825T polymorphism may not be a risk factor for FD.
RESUMO
In this study, a simple, sensitive, and robust analytical method based on ultra-performance liquid chromatography (UPLC) has been developed for the determination of trifolirhizin in rat plasma using pirfenidone as internal standard (IS). After sample preparation by a simple liquid-liquid extraction, chromatography was performed on an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7µm particle size) and ultraviolet detection set at a wavelength of 366nm. The method was linear over the concentration range 25-1000ng/mL with a lower limit of quantification (LLOQ) of 25ng/mL. Inter- and intra-day precision (RSD%) were all within 10.2% and the accuracy (RE%) was equal or lower than 9.3%. The recovery was in the range of 78.5-86.4% for trifolirhizin and 87.4% for IS. Stability studies showed that trifolirhizin was stable under a variety of storage conditions. The method was successfully applied to a pharmacokinetic study involving oral administration of trifolirhizin to rats.
